Brookfield Infrastructure Partners LP (BIP) Stock Price Today
Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Kodal Minerals secures up to 80% stake in Ghana lithium project, expanding West African presence.
Kodal Minerals PLC has acquired rights to up to 80% of the Asamankese lithium exploration project in Ghana, marking an expansion beyond its Mali operations. Early exploration shows high-grade lithium, with rock-chip samples up to 2.49% lithium oxide ...
Volex expects top-end profit forecast after record 21% revenue growth in H1 2026
Volex PLC, a UK manufacturer of power and data transmission products, reported a record first-half revenue increase of at least 21% to $710 million for the six months ending September 30, 2026. Growth was driven by aerospace, defence, electric vehicl...
Serica Energy maintains 2026 cash flow guidance despite Triton production delay
Serica Energy reported a delay in production at its Triton floating vessel due to extended maintenance, pushing output resumption to late November. Despite this, the company maintained its 2026 cash flow forecast of $450-$475 million, supported by st...
Defence Therapeutics wins Best Poster Award and leads key discussion at World ADC San Diego 2026
Defence Therapeutics Inc. received the Best Poster Award at World ADC San Diego 2026 for its innovative Accum®-ADC research and led a main-stage discussion on intracellular delivery in antibody-drug conjugates (ADCs). This recognition highlights the ...
Vanguard Dividend Appreciation ETF rated 'Hold' for missing high-yield dividend stocks due to its screening rules.
The Vanguard Dividend Appreciation ETF (VIG) is rated 'Hold' because its screening process excludes the highest-yielding 25% of dividend stocks, potentially missing undervalued opportunities. VIG focuses on companies with over 10 years of dividend gr...
Exelon rated BUY with 3.86% yield, strong growth outlook, and defensive utility model amid economic uncertainty.
Exelon (EXC) is rated a BUY due to its stable regulated utility business, offering a 3.86% dividend yield and attractive valuation after spinning off Constellation Energy. The company plans a 4-year capital growth strategy with 5% annual dividend gro...
T-Mobile shares drop $20B after SpaceX spectrum buy, but fundamentals remain strong for long-term investors.
T-Mobile's stock lost over $20 billion in value following SpaceX's $8 billion acquisition of 800 MHz spectrum, which T-Mobile had previously sold. Despite this setback, T-Mobile continues to show strong financial health with 9% year-over-year service...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.